Mulakan
GSK PLC LS-,3125GSK PLC LS-,3125GSK PLC LS-,3125

GSK PLC LS-,3125

Tiada dagangan
Lihat pada Carta Super
Gambaran keseluruhan Kewangan Idea Perbincangan Teknikal Ramalan Bermusim
Bon

Bon GS71

Di bawah adalah senarai bon-bon korporat GSK PLC LS-,3125. Pelabur selalunya memilih bon syarikat kerana kestabilan meningkat mereka semasa ketidakstabilan pasaran. Kaji harga, hasil dan statistik lain dan cari pelaburan yang boleh dipercayai.
Simbol
YTM %
Volum
Harga %
Kupon %
Tarikh Matang
Jumlah tertunggak
Nilai muka
Jumlah denominasi min
Pengeluar
GGSK3981911GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
6.42%1.87 M81.53%4.20%2043-03-18500 M USD1,000.00 USD2,000.00 USDGlaxoSmithKline Capital, Inc.
XXS217060907GLAXOSM.CAP. MTN 20/35MTN
6.42%070.86%1.63%2035-05-12750 M GBP1,000.00 GBP100,000.00 GBPGlaxoSmithKline Capital Plc
883GIGLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/20426.06%093.20%5.25%2042-04-10477.82 M GBP1,000.00 GBP50,000.00 GBPGlaxoSmithKline Capital Plc
117RIGLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/456.06%8.46 K82.51%4.25%2045-12-18370.79 M GBP1,000.00 GBP100,000.00 GBPGlaxoSmithKline Capital Plc
771ZCGLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/395.60%0106.00%6.38%2039-03-09631.3 M GBP1,000.00 GBP50,000.00 GBPGlaxoSmithKline Capital Plc
GGSK.GJGlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
5.47%160 K106.86%6.38%2038-05-152.75 B USD1,000.00 USD2,000.00 USDGlaxoSmithKline Capital, Inc.
GGSK6023693GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035
5.41%4.57 M96.56%4.88%2035-04-15750 M USD1,000.00 USD2,000.00 USDGlaxoSmithKline Capital, Inc.
AAG99GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/20334.88%0102.25%5.25%2033-12-19574.17 M GBP1,000.00 GBP1,000.00 GBPGlaxoSmithKline Capital Plc
GGSK6023692GlaxoSmithKline Capital Plc FRN 12-MAR-2027
4.79%8.74 M100.09%4.85%2027-03-12600 M USD1,000.00 USD2,000.00 USDGlaxoSmithKline Capital Plc
UUS377373AH8GLAXOSM.CAP. 19/29
4.71%095.49%3.38%2029-06-011 B USD1,000.00 USD2,000.00 USDGlaxoSmithKline Capital Plc
GGSK6023695GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030
4.70%3.72 M99.20%4.50%2030-04-15850 M USD1,000.00 USD2,000.00 USDGlaxoSmithKline Capital, Inc.
772WIGLAXOSMITHKLINE CAPITAL INC 5.375% GTD SNR NTS 15/04/20344.57%0105.28%5.38%2034-04-15500 M USD1,000.00 USD1,000.00 USDGlaxoSmithKline Capital, Inc.
XXS217060184GLAXOSM.CAP. MTN 20/28MTN
4.46%090.53%1.25%2028-10-12750 M GBP1,000.00 GBP100,000.00 GBPGlaxoSmithKline Capital Plc
UUS377372AN7GLAXOSMITHKLINE CAP.18/28
4.31%098.86%3.88%2028-05-151.75 B USD1,000.00 USD2,000.00 USDGlaxoSmithKline Capital, Inc.
GGSK6023691GlaxoSmithKline Capital Plc 4.315% 12-MAR-2027
4.16%3 M100.26%4.32%2027-03-12400 M USD1,000.00 USD2,000.00 USDGlaxoSmithKline Capital Plc
XXS293369275GSK CAP B.V. 24/36 MTN
3.87%095.10%3.25%2036-11-19600 M EUR1,000.00 EUR100,000.00 EURGSK Capital BV
XXS255381776GSK CAP B.V. 22/32 MTN
3.41%098.29%3.13%2032-11-28700 M EUR1,000.00 EUR100,000.00 EURGSK Capital BV
XXS293369143GSK CAP B.V. 24/31 MTN
3.21%098.21%2.88%2031-11-19700 M EUR1,000.00 EUR100,000.00 EURGSK Capital BV
XXS182282979GLAXOSM.CAP. MTN 18/30MTN
3.05%094.36%1.75%2030-05-21750 M EUR1,000.00 EUR100,000.00 EURGlaxoSmithKline Capital Plc
GGX5CGLAXOSM.CAP. MTN 05/25
2.86%0100.08%4.00%2025-06-16750 M EUR1,000.00 EUR1,000.00 EURGlaxoSmithKline Capital Plc
XXS168152035GLAXOSM.CAP. MTN 17/29
2.79%094.54%1.38%2029-09-12500 M EUR1,000.00 EUR100,000.00 EURGlaxoSmithKline Capital Plc
XXS255381768GSK CAP B.V. 22/27 MTN
2.45%0101.30%3.00%2027-11-28500 M EUR1,000.00 EUR100,000.00 EURGSK Capital BV
XXS182282812GLAXOSM.CAP. MTN 18/26MTN
2.24%099.03%1.25%2026-05-211 B EUR1,000.00 EUR100,000.00 EURGlaxoSmithKline Capital Plc
GGX5BGLAXOSM.CAP. MTN 17/26
2.20%098.47%1.00%2026-09-12700 M EUR1,000.00 EUR100,000.00 EURGlaxoSmithKline Capital Plc
117RNGLAXOSMITHKLINE CAPITAL PLC 3.375% GTD SNR EMTN 20/12/20270.84%0112.19%3.38%2027-12-20307.77 M GBP1,000.00 GBP100,000.00 GBPGlaxoSmithKline Capital Plc
AAQ72GLAXOSMITHKLINE CAPITAL PLC 0.883% GTD SNR EMTN 21/09/20———0.88%2028-09-2142.5 B JPY100,000,000.00 JPY100,000,000.00 JPYGlaxoSmithKline Capital Plc